Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Pain Manag ; 8(5): 363-375, 2018 Sep 01.
Article in English | MEDLINE | ID: mdl-30212277

ABSTRACT

The burdensome condition of chemotherapy-induced peripheral neuropathy occurs with various chemotherapeutics, including bortezomib, oxaliplatin, paclitaxel and vincristine. The symptoms, which include pain, numbness, tingling and loss of motor function, can result in therapy titrations that compromise therapy efficacy. Understanding the mechanisms of chemotherapy-induced peripheral neuropathy is therefore essential, yet incompletely understood. The literature presented here will address a multitude of molecular and cellular mechanisms, beginning with the most well-understood cellular and molecular-level changes. These modifications include alterations in voltage-gated ion channels, neurochemical transmission, organelle function and intracellular pathways. System-level alterations, including changes to glial cells and cytokine activation are also explored. Finally, we present research on the current understanding of genetic contributions to this condition. Suggestions for future research are provided.


Subject(s)
Antineoplastic Agents/adverse effects , Peripheral Nervous System Diseases/chemically induced , Animals , Humans , Peripheral Nervous System Diseases/genetics , Peripheral Nervous System Diseases/metabolism , Peripheral Nervous System Diseases/physiopathology
2.
Neurosci Lett ; 682: 21-26, 2018 08 24.
Article in English | MEDLINE | ID: mdl-29885448

ABSTRACT

Methylphenidate (MPH) and methamphetamine (METH) are two commonly abused psychomotor stimulants that impact anxiety, but in a manner that is currently unclear. This study adds to the literature by testing the effects of MPH and METH on anxiety in adult female rats, which has not previously been studied. In Experiment1, changes in anxiety-like behavior were determined using the Elevated Plus Maze (EPM) following either an acute injection of saline, METH (1 mg/kg), or MPH (10 mg/kg). Changes in general locomotion were measured using the open field test. MPH, but not METH, significantly decreased anxiety; MPH and METH were associated with increased activity in the open field. In Experiment2, we compared the effects of three once daily injections of saline to MPH (10 mg/kg) or METH (1 mg/kg). As with the acute dosing, repeated exposure to MPH, but not METH, decreased anxiety, and both drugs increased locomotion. Neither acute nor chronic dosing produced a change in locomotion during the EPM, indicating that the anxiolytic effects of MPH are independent of changes in locomotor behavior. These findings add further clarification to the literature investigating the psychoactive properties of MPH, with a special and needed emphasis on female behavior.


Subject(s)
Anti-Anxiety Agents/administration & dosage , Anxiety/drug therapy , Illicit Drugs , Methamphetamine/administration & dosage , Methylphenidate/administration & dosage , Animals , Anxiety/psychology , Dopamine Uptake Inhibitors/administration & dosage , Dose-Response Relationship, Drug , Exploratory Behavior/drug effects , Exploratory Behavior/physiology , Female , Locomotion/drug effects , Locomotion/physiology , Maze Learning/drug effects , Maze Learning/physiology , Rats , Rats, Long-Evans
3.
Pain Manag ; 5(4): 285-96, 2015.
Article in English | MEDLINE | ID: mdl-26087973

ABSTRACT

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition seen in patients undergoing treatment with common agents such as vincristine, paclitaxel, oxaliplatin and bortezomib. The mechanisms of this condition are diverse, and include an array of molecular and cellular contributions. Current research implicates genetic predispositions to this condition, which then may influence cellular responses to chemotherapy. Processes found to be influenced during CIPN include increased expression of inflammatory mediators, primarily cytokines, which can create cascading effects in neurons and glia. Changes in ion channels and neurotransmission, as well as changes in intracellular signaling and structures have been implicated in CIPN. This review explores these issues and suggests considerations for future research.


Subject(s)
Antineoplastic Agents/adverse effects , Neoplasms/drug therapy , Peripheral Nervous System Diseases/chemically induced , Cellular Structures/drug effects , Cytokines/drug effects , Cytokines/metabolism , Humans , Ion Channels/drug effects , Mechanoreceptors/drug effects , Neoplasms/genetics , Nerve Fibers/drug effects , Neuroglia/drug effects , Peripheral Nervous System Diseases/genetics , Signal Transduction/drug effects , Synaptic Transmission/drug effects , Transient Receptor Potential Channels/drug effects
4.
J Clin Oncol ; 32(28): 3156-62, 2014 Oct 01.
Article in English | MEDLINE | ID: mdl-25154818

ABSTRACT

PURPOSE: The goal in this study was to determine the incidence of subclinical neuropathy in treatment-naive patients with multiple myeloma (MM) with no history of peripheral neuropathy using quantitative sensory tests (QSTs) and its correlation with innervation density of the extremities using noninvasive laser reflectance confocal microscopy. PATIENTS AND METHODS: QST results were collected for 27 patients with a diagnosis of MM and compared with data collected from 30 age- and sex-matched healthy volunteers. Skin temperature, sensorimotor function (grooved pegboard test), and detection thresholds for temperature, sharpness, and low-threshold mechanical stimuli (von Frey monofilaments and bumps detection test) were measured. Meissner's corpuscle (MC) density in the fingertips was assessed using in vivo laser reflectance confocal microscopy. RESULTS: Patients showed a high incidence (> 80%) of ≥ one subclinical QST deficit. These included increased von Frey, bumps, and warmth detection thresholds as compared with healthy volunteers. Patients also showed increases in cold pain, sensorimotor deficits (grooved pegboard test), and higher overall neuropathy scores. MC density was significantly lower in patients than controls and showed significant inverse correlation with bumps detection threshold. CONCLUSION: Patients with MM commonly present with sensory and sensorimotor deficits before undergoing treatment, and these deficits seem to result from disease-related decreases in peripheral innervation density.


Subject(s)
Fingers/innervation , Multiple Myeloma/complications , Peripheral Nervous System Diseases/diagnosis , Peripheral Nervous System Diseases/physiopathology , Aged , Case-Control Studies , Cold Temperature , Female , Hot Temperature , Humans , Male , Microscopy, Confocal , Middle Aged , Neurologic Examination/methods , Peripheral Nervous System Diseases/etiology , Sensorimotor Cortex/physiopathology , Sensory Thresholds , Skin Temperature
5.
Article in English | MEDLINE | ID: mdl-24829554

ABSTRACT

The neural network that contributes to the suffering which accompanies persistent pain states involves a number of brain regions. Of primary interest is the contribution of the cingulate cortex in processing the affective component of pain. The purpose of this review is to summarize recent data obtained using novel behavioral paradigms in animals based on measuring escape and/or avoidance of a noxious stimulus. These paradigms have successfully been used to study the nature of the neuroanatomical and neurochemical contributions of the anterior cingulate cortex (ACC) to higher order pain processing in rodents.

6.
J Pain ; 14(10): 1031-44, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23726937

ABSTRACT

UNLABELLED: The use of paclitaxel (Taxol), a microtubule stabilizer, for cancer treatment is often limited by its associated peripheral neuropathy (chemotherapy-induced peripheral neuropathy [CIPN]), which predominantly results in sensory dysfunction, including chronic pain. Here we show that paclitaxel CIPN was associated with induction of chemokine monocyte chemoattractant protein-1 (MCP-1) and its cognate receptor CCR2 in primary sensory neurons of dorsal root ganglia. Immunostaining revealed that MCP-1 was mainly expressed in small nociceptive neurons whereas CCR2 was expressed in large and medium-sized myelinated neurons. Direct application of MCP-1 consistently induced intracellular calcium increases in dorsal root ganglia large and medium-sized neurons but not in small neurons mainly dissociated from paclitaxel-treated but not vehicle-treated animals. Paclitaxel also induced increased expression of MCP-1 in spinal astrocytes, but no CCR2 signal was detected in the spinal cord. Local blockade of MCP-1/CCR2 signaling by anti-MCP-1 antibody or CCR2 antisense oligodeoxynucleotides significantly attenuated paclitaxel CIPN phenotypes including mechanical hypersensitivity and loss of intraepidermal nerve fibers in hindpaw glabrous skin. These results suggest that activation of paracrine MCP-1/CCR2 signaling between dorsal root ganglion neurons plays a critical role in the development of paclitaxel CIPN, and targeting MCP-1/CCR2 signaling could be a novel therapeutic approach. PERSPECTIVE: CIPN is a severe side effect accompanying paclitaxel chemotherapy and lacks effective treatments. The current study suggests that blocking MCP-1/CCR2 signaling could be a new therapeutic strategy to prevent or reverse paclitaxel CIPN. This preclinical evidence encourages future clinical evaluation of this strategy.


Subject(s)
Antineoplastic Agents, Phytogenic/adverse effects , Chemokine CCL2/drug effects , Paclitaxel/adverse effects , Peripheral Nervous System Diseases/chemically induced , Receptors, CCR2/drug effects , Sensory Receptor Cells/drug effects , Animals , Calcium/metabolism , Female , Ganglia, Spinal/drug effects , Ganglia, Spinal/pathology , Immunohistochemistry , Injections, Spinal , Pain Threshold/drug effects , Peripheral Nervous System Diseases/pathology , Physical Stimulation , Posterior Horn Cells/drug effects , Rats , Rats, Sprague-Dawley , Real-Time Polymerase Chain Reaction
7.
Cancer Chemother Pharmacol ; 71(6): 1531-40, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23543296

ABSTRACT

PURPOSE: Chemotherapy-induced peripheral neuropathy is a major complication in the treatment for cancer, including multiple myeloma (MM). Patients may develop painful and non-painful (e.g., numbness) neuropathy symptoms that impair function and often persist after therapy is terminated. This study tested the hypothesis that baseline subclinical neuropathy, as assessed by sensory thresholds, is related to the development of neuropathy symptoms (e.g., pain and numbness) in patients with MM undergoing treatment with chemotherapy. METHODS: Patients (n = 56) who had undergone two or fewer cycles of induction therapy and who had no evident neuropathy were assessed using quantitative sensory tests to determine multiple-modality sensory thresholds. Patient-reported pain and numbness were assessed through induction therapy (16 weeks) via the MD Anderson Symptom Inventory. A subset of participants (n = 15) continued reporting on their symptoms for an additional 16 weeks ("maintenance phase"). RESULTS: Patients with sharpness detection deficits at baseline (n = 11, 20 % of sample) reported less severe pain and numbness during induction therapy and less numbness during maintenance therapy (P < 0.05). During the maintenance phase, patients with warmth detection deficits (n = 5, 38 % of sample) reported more severe pain and numbness, and those with skin temperature deficits (n = 7, 47 % of maintenance sample) reported more severe pain (P < 0.05). These deficits were related to patient reported difficulty walking, a common symptom of peripheral neuropathy. CONCLUSION: Our results suggest that baseline subclinical sensory deficits may be related to a patient's risk for developing chemotherapy-induced peripheral neuropathy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Hypesthesia/chemically induced , Multiple Myeloma/drug therapy , Pain/chemically induced , Peripheral Nervous System Diseases/chemically induced , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Female , Humans , Hypesthesia/psychology , Male , Middle Aged , Multiple Myeloma/physiopathology , Pain/psychology , Peripheral Nervous System Diseases/psychology , Predictive Value of Tests , Sensory Thresholds/physiology , Surveys and Questionnaires
8.
Cancer Chemother Pharmacol ; 71(3): 619-26, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23228992

ABSTRACT

PURPOSE: Chemoneuropathy remains a painful, burdensome complication of cancer treatment for patients receiving a range of chemotherapeutics, yet the cause and persistence of this condition are not fully documented. This study was designed to quantify the longevity of and contributions to neuropathy following treatment with the plant alkaloids paclitaxel and vincristine. METHODS: Quantitative sensory testing was conducted approximately 18 months apart on 14 patients, seven of which had been treated with paclitaxel and seven with vincristine and compared to data from 18 healthy control subjects. In addition, skin biopsies were obtained to investigate changes in the density of Meissner's corpuscles and epidermal nerve fibers (ENFs), the loss of which is thought to contribute to multiple forms of neuropathy. RESULTS: Impairments in motor skills, as measured by a grooved peg-board, were found. Deficits in touch detection were observed using von Frey monofilaments, as were changes in sharpness detection using a weighted needle device. Using a Peltier device, warmth and heat detection were impaired. These deficits were consistent across time. Remarkably, the average length of time patients reported painful neuropathy was over four and a half years. Skin biopsies were found to be deficient in Meissner's corpuscles and ENFs. CONCLUSIONS: The combination of widespread deficits in sensory testing and decreases in skin innervation for cancer patients receiving paclitaxel or vincristine document a persistent polyneuropathy which severely impacts these patients. Decreases in Meissner's corpuscles and ENFs indicate a possible mechanism for the neuropathy.


Subject(s)
Antineoplastic Agents, Phytogenic/adverse effects , Neurotoxicity Syndromes/pathology , Paclitaxel/adverse effects , Peripheral Nervous System Diseases/chemically induced , Vincristine/adverse effects , Aged , Antineoplastic Agents, Phytogenic/therapeutic use , Biopsy , Female , Humans , Male , Mechanoreceptors/drug effects , Middle Aged , Motor Skills/drug effects , Nerve Fibers/pathology , Paclitaxel/therapeutic use , Pain/chemically induced , Pain Measurement/drug effects , Peripheral Nervous System Diseases/pathology , Physical Stimulation , Pilot Projects , Sensory Thresholds/drug effects , Skin/innervation , Skin/pathology , Thermosensing/drug effects , Touch/drug effects , Vincristine/therapeutic use
9.
Clin Cancer Res ; 18(11): 3180-7, 2012 Jun 01.
Article in English | MEDLINE | ID: mdl-22496202

ABSTRACT

PURPOSE: Of the numerous complications associated with cancer and cancer treatment, peripheral neuropathy is a deleterious and persistent patient complaint commonly attributed to chemotherapy. The present study investigated the occurrence of subclinical peripheral neuropathy in patients with colorectal cancer before the initiation of chemotherapy. EXPERIMENTAL DESIGN: Fifty-two patients underwent extensive quantitative sensory testing (QST) before receiving chemotherapy. Changes in multiple functions of primary afferent fibers were assessed and compared with a group of healthy control subjects. Skin temperature, sensorimotor function, sharpness detection, and thermal detection were measured, as was touch detection, using both conventional (von Frey monofilaments) and novel (Bumps detection test) methodology. RESULTS: Patients had subclinical deficits, especially in sensorimotor function, detection of thermal stimuli, and touch detection that were present before the initiation of chemotherapy. The measured impairment in touch sensation was especially pronounced when using the Bumps detection test. CONCLUSIONS: The patients with colorectal cancer in this study exhibited deficits in sensory function before undergoing chemotherapy treatment, implicating the disease itself as a contributing factor in chemotherapy-induced peripheral neuropathy. The widespread nature of the observed deficits further indicated that cancer is affecting multiple primary afferent subtypes. Specific to the finding of impaired touch sensation, results from this study highlight the use of newly used methodology, the Bumps detection test, as a sensitive and useful tool in the early detection of peripheral neuropathy.


Subject(s)
Colorectal Neoplasms/complications , Peripheral Nervous System Diseases/etiology , Female , Humans , Male , Pain Measurement/methods , Peripheral Nervous System Diseases/diagnosis , Sensation , Skin Temperature
10.
J Pain ; 12(9): 1017-24, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21703938

ABSTRACT

UNLABELLED: Many frontline chemotherapeutic agents produce robust neuropathy as a dose-limiting side effect; however, the persistence of chemotherapy-related sensory disturbances and pain are not well documented. We have previously investigated the qualities of bortezomib-induced pain, and now seek to determine the ongoing nature of this pain. Twenty-six control subjects and 11 patients who had previously been treated with bortezomib and who were experiencing ongoing pain consented to recurring quantitative sensory testing. A pilot immunohistochemistry study of skin innervation was also performed on patient-obtained biopsies. Psychophysical testing in patients revealed persistent changes including decreased skin temperature in the area of pain, diminished touch and sharpness detection, increased pegboard completion times, and decreased sensitivity to skin heating. Additionally, the intensity of pain, as captured by the use of a visual analog scale and pain descriptors, was reported by patients to be unchanged during the retest despite similar morphine equivalent daily doses. The patient skin biopsies displayed a marked decrease in the density of epidermal nerve fibers and Meissner's corpuscles. These results signify a persistent and severe impairment of Aß, Aδ, and C fibers in patients with chronic bortezomib-induced chemoneuropathy. Further, this study reports a loss of both epidermal nerve fibers and Meissner's corpuscles. PERSPECTIVE: The results of this article indicate a persistent, painful peripheral neuropathy in patients treated with bortezomib. Pilot data indicates a loss of nerve fibers innervating the area of pain. This is the first paper to address the persistence, and potential contributing factors, of bortezomib chemoneuropathy.


Subject(s)
Antineoplastic Agents/adverse effects , Boronic Acids/adverse effects , Pain/chemically induced , Pain/psychology , Peripheral Nervous System Diseases/chemically induced , Peripheral Nervous System Diseases/psychology , Pyrazines/adverse effects , Bortezomib , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pain Measurement/methods , Peripheral Nervous System Diseases/physiopathology , Pilot Projects
11.
Pharmacol Biochem Behav ; 98(2): 325-30, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21277888

ABSTRACT

The overall impact of chronic pain on the response to opioids is ambiguous in the literature, and comparisons between human and animal studies are complicated by vast differences between the manner and dosage of opioids given to humans treated for pain in comparison to rodents as well as a lack of healthy participant studies examining the impact of chronic opioids. The purpose of this study was to evaluate the impact of chronic pain on the development of tolerance to morphine and to assess how the concentration of drug affects this process. Twenty-four hours after the injection of CFA or normal saline in the left hind paw, the level of mechanical hypersensitivity was assessed and animals were randomly assigned to a morphine dose (1, 3 or 8 mg/kg or saline). Morphine was administered by subcutaneous injection twice a day for 5 days. On Day 6, animals were challenged with a single dose of 3 mg/kg morphine prior to formalin testing. Evidence of tolerance was mixed, and the results varied widely among the conditions. Analysis of mean paw withdrawal thresholds indicated that the analgesic efficacy of subcutaneous morphine diminished following repeated dosing. The presence of the chronic inflammatory pain condition during the morphine dosing period produced an increase in formalin pain behaviors compared to saline controls, such that animals given any dose of morphine during the 5-day dosing period showed higher responding to formalin following the 3 mg/kg dose than animals that had received saline injections. These results indicate that chronic pain does influence the development of opioid tolerance, but it does not prevent this phenomenon from occurring as suggested by some researchers.


Subject(s)
Drug Tolerance/physiology , Morphine Dependence/etiology , Pain/physiopathology , Pain/psychology , Animals , Chronic Disease , Disease Models, Animal , Humans , Inflammation/physiopathology , Inflammation/psychology , Male , Morphine/administration & dosage , Morphine Dependence/physiopathology , Morphine Dependence/psychology , Pain/drug therapy , Pain Measurement , Rats , Rats, Sprague-Dawley , Species Specificity
12.
Neurosci Lett ; 453(3): 170-4, 2009 Apr 10.
Article in English | MEDLINE | ID: mdl-19429028

ABSTRACT

Treatment for cancer has been indicated to negatively impact the quality of life for patients. Specifically, chemotherapy has been associated with fatigue, nausea, and peripheral neuropathy. More recently, chemotherapy has been found to be related to cognitive impairment in various domains including working memory, information processing speed, and visual attention. At this time, the mechanisms underlying cognitive impairment are not understood, and there is currently no treatment for this condition. The purpose of this study was to examine the development of chemotherapy-induced cognitive impairments and symptoms of peripheral neuropathy. While receiving the chemotherapeutic agent Taxol, animals were tested daily in the Five Choice Serial Reaction Time Task (5CSRTT), a task which requires animals to respond to a visually presented stimulus in order to obtain reinforcement. In addition, animals were tested for the development of peripheral neuropathy, measured by changes in sensitivity to mechanical stimulation. The results indicate Taxol treated animals developed mechanical sensitivity within 24h after the first injection of chemotherapy. However, relative to control animals, Taxol treated animals did not exhibit alterations in cognitive function in the 5CSRTT. These differential findings may provide interesting insight into the mechanisms underlying chemotherapy-related cognitive impairment.


Subject(s)
Antineoplastic Agents, Phytogenic/adverse effects , Cognition Disorders/chemically induced , Paclitaxel/adverse effects , Peripheral Nervous System Diseases/chemically induced , Animals , Cognition/drug effects , Cognition Disorders/psychology , Conditioning, Operant/drug effects , Male , Peripheral Nervous System Diseases/psychology , Physical Stimulation , Rats , Rats, Long-Evans , Reaction Time/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...